Recently published Warm Autoimmune Hemolytic Anemia Market Insights report includes a comprehensive understanding of current ...

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and ...

The FDA’s approval of inebilizumab has heralded a new era for patients with IgG4-related disease, while novel agents moving ...

Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose disease stops responding to existing ...

Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.

Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics. The licensing ...

CHARLOTTE — The investigational oral Bruton tyrosine kinase inhibitor (BTKi) fenebrutinib significantly outperformed teriflunomide on relapse and MRI outcomes, marking the first potential win ...

• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...

• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...